Vodobatinib works by suppressing an enzyme called Abl tyrosine kinase, whose activity has been linked to several Parkinson’s processes such as inflammation and alpha-synuclein-induced neurodegeneration.

Sun Pharma Advanced Research Company (SPARC) is conducting a Phase ll clinical trial to evaluate the safety and effectiveness of its experimental c-Abl inhibitor vodobatinib (previously known as KO706) in people with early Parkinson’s. The trial of 500 participants, will randomly assign participants to receive the drug or placebo for nine months.

Results of SPARC’s pivotal Phase l study, which evaluated the safety and tolerability of ascending doses of vodobatinib, showed that the therapy was well-tolerated and allowed the selection of two doses likely to produce therapeutic effects.

The double-blind, placebo-controlled PROSEEK study will evaluate the safety and effectiveness of the two selected vodobatinib doses in people with early Parkinson’s who are not receiving any dopaminergic therapy.

The study’s primary goal is to assess changes in patients’ motor functions. Researchers will also assess the drug’s impact on the health of dopamine-producing neurons in Parkinson’s patients through specialised (DaT SPECT) brain imaging.

DaT SPECT is a highly sensitive imaging tool capable of distinguishing people with Parkinson’s from unaffected people even in early stages of the disease. DaT SPECT images will be able to help determine the density of healthy dopamine-producing neurons in the participant’s brain.

Results of this proof of concept trial, if found to be positive, are expected to support the advancement of vodobatinib into phase lll clinical studies for Parkinson’s.

Source: Parkinson’s News Today – September 2019

How helpful was this content?

/ 5. Vote count: